Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE versus FELBATOL.
DEPAKOTE vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant